Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $1,252.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective dropped by Royal Bank of Canada from $1,282.00 to $1,252.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 21.91% from the stock’s previous close.

A number of other analysts have also commented on REGN. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. Barclays increased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Finally, Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,118.62.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $65.00 during trading on Tuesday, hitting $1,026.98. 762,223 shares of the stock traded hands, compared to its average volume of 474,239. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20. The stock has a market cap of $113.16 billion, a price-to-earnings ratio of 30.34, a P/E/G ratio of 3.93 and a beta of 0.12. The company has a 50 day simple moving average of $1,131.94 and a 200 day simple moving average of $1,033.46. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,270 shares of company stock valued at $10,695,833. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. West Paces Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.